Skip to Main Content

French drug maker Sanofi said Wednesday that it will acquire Kadmon Pharmaceuticals for $1.9 billion, bolstering its transplant medicines business with a newly approved treatment for graft-versus-host disease.

The all-cash transaction sees Kadmon shares worth $9.50 per share, or a 79% premium to Tuesday’s closing price.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment